Article
Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.
Bioorganic chemistry - 15 Aug 2026
Fu Wenying, Yan Ying, Tian Fei, Shu Chongchong, Yang Fan, Xia Yiqun, Chen Xiao, Chen Jundixia, Jiang Yiyan, Cui Ri, Zou Peng, Ni Daoyong, Chen Yunzhi
Abstract excerpt
KRAS-mutant tumors remain a major challenge in cancer therapy. Although current targeted drugs show initial promise, their efficacy is often limited by the development of resistance. Therefore, identifying effective drug combinations to target KRAS-mutant tumors is of great significance. This study investigates the synergistic potential of romidepsin (RO), a class I HDAC inhibitor, in combination with adagrasib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.